The University of Texas Health Science Center at Houston, 6410 Fannin St Suite 830, Houston, TX 77030, USA.
Future Oncol. 2012 Mar;8(3):231-7. doi: 10.2217/fon.12.7.
This paper reviews the development of the combination of modified vaccinia Ankara (MVA) to deliver the tumor-associated antigen 5T4 as a novel immunotherapeutic vaccine. The oncofetal antigen 5T4 is highly expressed in 80% of breast, kidney, colorectal, prostate and ovarian carcinomas, making it an ideal antigen for vaccine therapy. To date, more than 3000 doses of MVA-5T4 have been administered to colorectal, renal and prostate cancer patients, with rare occurrences of grade 3 or 4 vaccination-related adverse events being observed. Studies have demonstrated that MVA-5T4 is safe and highly immunogenic, both as monotherapy and in combination with other standard of care therapies. Although an immune response has been observed, antitumor activity has been modest or absent in clinical trials. A Phase III trial resulted in the development of an immune response surrogate that is to be applied to all future MVA-5T4 clinical trials. With minimal side effects and the ability to produce a strong immunogenic response, MVA-5T4 is a viable addition to the cancer therapy arsenal.
本文回顾了改良安卡拉痘苗病毒（MVA）与肿瘤相关抗原 5T4 结合作为新型免疫治疗疫苗的发展。癌胚抗原 5T4 在 80%的乳腺癌、肾癌、结直肠癌、前列腺癌和卵巢癌中高度表达，使其成为疫苗治疗的理想抗原。迄今为止，已有超过 3000 剂 MVA-5T4 用于结直肠癌、肾癌和前列腺癌患者，仅观察到罕见的 3 级或 4 级与疫苗接种相关的不良事件。研究表明，MVA-5T4 是安全且具有高度免疫原性的，无论是作为单一疗法还是与其他标准治疗方法联合使用。尽管观察到了免疫反应，但临床试验中的抗肿瘤活性较低或不存在。一项 III 期试验产生了一种免疫反应替代物，将应用于所有未来的 MVA-5T4 临床试验。MVA-5T4 具有最小的副作用和产生强烈免疫原性反应的能力，是癌症治疗武器库的可行选择。
